Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $25.0M | — | — | — | — | $0.00 | $925K | $0.00 |
| Revenue growth | — | — | — | — | — | — | — | — | — | -100.0% |
| Operating income | -$37.6M | -$51.1M | -$32.6M | -$71.0M | -$33.7M | -$60.7M | -$56.5M | -$55.6M | -$82.6M | -$103M |
| Operating margin | — | — | -130.5% | — | — | — | — | — | -8930.3% | — |
| Net income | -$37.0M | -$50.2M | -$31.6M | -$69.4M | -$33.3M | -$60.7M | -$55.2M | -$36.3M | -$75.1M | -$90.4M |
| Net margin | — | — | -126.3% | — | — | — | — | — | -8123.7% | — |
| EPS (diluted) | -$1.96 | -$2.14 | -$1.34 | -$2.57 | -$0.64 | -$1.10 | -$1.04 | — | -$4.28 | -$4.24 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$30.2M | -$44.7M | -$31.6M | -$15.4M | -$24.6M | -$47.6M | -$52.8M | -$51.4M | -$70.6M | -$77.2M |
| Capital expenditures | $713K | $494K | $49.0K | $879K | $2.22M | $3.26M | $2.23M | $321K | $808K | $1.18M |
| Free cash flow | -$30.9M | -$45.2M | -$31.6M | -$16.3M | -$26.8M | -$50.8M | -$55.1M | -$51.7M | -$71.4M | -$78.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $32.3M | $52.0M | $76.9M | $143M | $193M | $142M | $82.0M | $148M | $137M | $104M |
| Total assets | $154M | $110M | $77.6M | $147M | $211M | $163M | $109M | $223M | $336M | $289M |
| Total liabilities | $9.72M | $11.4M | $4.95M | $5.34M | $19.3M | $20.4M | $10.6M | $36.5M | $25.4M | $23.7M |
| Shareholders' equity | $145M | $98.9M | $72.7M | $142M | $191M | -$91.9M | -$146M | $186M | $310M | $265M |
| Retained earnings | -$148M | -$199M | -$230M | -$300M | -$333M | -$393M | -$151M | -$187M | -$262M | -$353M |
| Shares (wtd avg diluted) | 23.4M | 23.5M | 23.5M | 38.0M | 51.8M | 55.0M | 55.2M | 12.8M | 17.6M | 21.3M |
Every figure is extracted from Neurogene Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.